Type 2 Amiodarone-induced Thyrotoxicosis Which Presented with Nodular goiter

Amiodarone, an iodinated benzofuranic derivative, was introduced in the 1960s as an antianginal agent for its coronary vasodilator property. Later it was broadly applied as an antiarrhythmic agent. Amiodarone affects thyroid function as a result of both iodine release and intrinsic drug properties. The incidence of Amiodarone induced thyrotoxicosis (AIT) is 5-10% in reports of most studies. There are two types of AIT, designated as type 1 and type 2. Type 1 AIT occurs in abnormal thyroid glands (nodular goiter, latent Graves’ disease) and type 2 AIT in apparently normal thyroid glands. But mixed or indefinite form, the combination of these 2 forms does exist. This form maybe caused by both pathogenic mechanisms. Here we reported a patient with type 2 AIT who presented not only with common manifestations of type 1AIT but also gained euthyroid state with steroid therapy.

[1]  Elena S. Di Martino,et al.  Amiodarone and the thyroid: A 2012 update , 2012, Journal of Endocrinological Investigation.

[2]  F. Bogazzi,et al.  Approach to the patient with amiodarone-induced thyrotoxicosis. , 2010, The Journal of clinical endocrinology and metabolism.

[3]  W. Wiersinga,et al.  Diagnosis and management of amiodarone‐induced thyrotoxicosis: similarities and differences between North American and European thyroidologists * , 2008, Clinical endocrinology.

[4]  M. Piga,et al.  The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. , 2008, European journal of endocrinology.

[5]  L. Braverman,et al.  The effects of amiodarone on the thyroid. , 2001, Endocrine reviews.

[6]  L. Braverman,et al.  Serum interleukin-6 in amiodarone-induced thyrotoxicosis. , 1994, The Journal of clinical endocrinology and metabolism.

[7]  C. Kao,et al.  Quick diagnosis of hyperthyroidism with semiquantitative 30-minute technetium-99m-methoxy-isobutyl-isonitrile thyroid uptake. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  C. Kao,et al.  Visualization of Suppressed Thyroid Tissue by Tc‐99m MIBI , 1991, Clinical nuclear medicine.

[9]  J. Kronauge,et al.  Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  B. Holman,et al.  Noncardiac applications of hexakis(alkylisonitrile) technetium-99m complexes. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  Alun G. Jones,et al.  Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. , 1990, Cancer research.

[12]  M. L. Santos,et al.  Antithyroid antibodies as an early marker for thyroid disease induced by amiodarone. , 1986, British medical journal.